Results 21 to 30 of about 21,670 (174)

A simple LC-MS/MS method for pharmacokinetic study of carvedilol and 4/-hydroxyphenyl carvedilol at a low dose

open access: yesResearch in Pharmaceutical Sciences, 2022
Background and purpose: The study was aimed at validating a simple, rapid, and low-cost LC-MS/MS method for carvedilol and 4/-hydroxyphenyl carvedilol assay in human plasma. The validated method was applied to investigate the pharmacokinetics after a low
Wanna Eiamart   +5 more
doaj   +1 more source

Comparative Study of Selected Excipients’ Influence on Carvedilol Release from Hypromellose Matrix Tablets

open access: yesPharmaceutics, 2023
Solid dosage forms based on hypromellose (HPMC) with prolonged/extended drug release are very important from the research and industrial viewpoint. In the present research, the influence of selected excipients on carvedilol release performance from HPMC ...
Tadej Ojsteršek   +2 more
doaj   +1 more source

Drug-Drug Interactions of Cenobamate With Medications: Dose-Dependent Induction/Inhibition and Clinical Implications. [PDF]

open access: yesCPT Pharmacometrics Syst Pharmacol
ABSTRACT Cenobamate causes dose‐dependent cytochrome P450 (CYP)2B6 and CYP3A4 induction and CYP2C19 inhibition, raising concern over multi‐pathway drug–drug interactions (DDIs) in patients with epilepsy treated with cardiovascular co‐medications. We developed a physiologically based pharmacokinetic (PBPK) model for cenobamate and verified it using ...
Ichida H   +7 more
europepmc   +2 more sources

Role of GRK5/β-arrestin2 pathway in mediating the cardioprotective effects of carvedilol in 5/6 nephrectomized rats [PDF]

open access: yesZagazig University Medical Journal, 2022
Background: Cardiorenal-syndrome is associated with high morbidity and mortality rates. This study tries to clarify the cardio-protective effects of carvedilol in 5/6 nephrectomized rats. Methods: The current study involved five groups of rats: sham, 5/6
Rasha Mohamed   +3 more
doaj   +1 more source

Central composite design for the development of carvedilol-loaded transdermal ethosomal hydrogel for extended and enhanced anti-hypertensive effect

open access: yesJournal of Nanobiotechnology, 2021
Background Carvedilol, the anti-hypertensive drug, has poor bioavailability when administered orally. Ethosomes-mediated transdermal delivery is considered a potential route of administration to increase the bioavailability of carvedilol.
Padmanabha Rao Amarachinta   +5 more
doaj   +1 more source

Mechanism of carvedilol induced action potential and calcium alternans

open access: yesChannels, 2022
Carvedilol is a nonspecific β-blocker clinically used for the treatment of cardiovascular diseases but has also been shown to have profound effects on excitation-contraction coupling and Ca signaling at the cellular level. We investigate the mechanism by
Elizabeth Martinez-Hernandez   +2 more
doaj   +1 more source

In silico drug repurposing carvedilol and its metabolites against SARS-CoV-2 infection using molecular docking and molecular dynamic simulation approaches

open access: yesScientific Reports, 2023
The pandemic of coronavirus disease 2019 (COVID-19) caused by the infection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has caused a significant impact on the economy and public health worldwide.
Chunye Zhang   +4 more
doaj   +1 more source

Tip loaded cyclodextrin-carvedilol complexes microarray patches [PDF]

open access: yes, 2023
Carvedilol, a β-blocker prescribed for chronic heart failure, suffers from poor bioavailability and rapid first pass metabolism when administered orally. Herein, we present the development of tip microarray patches (MAPs) composed of ternary cyclodextrin
Bin Sabri, Akmal Hidayat   +11 more
core   +1 more source

Long‐Term Mortality Associated With Use of Carvedilol Versus Metoprolol in Heart Failure Patients With and Without Type 2 Diabetes: A Danish Nationwide Cohort Study

open access: yesJournal of the American Heart Association: Cardiovascular and Cerebrovascular Disease, 2021
Background Carvedilol may have favorable glycemic properties compared with metoprolol, but it is unknown if carvedilol has mortality benefit over metoprolol in patients with type 2 diabetes (T2D) and heart failure with reduced ejection fraction (HFrEF ...
Brian Schwartz   +8 more
doaj   +1 more source

Chitosan as Valuable Excipient for Oral and Topical Carvedilol Delivery Systems

open access: yesPharmaceuticals, 2021
Chitosan is a valued excipient due to its biocompatibility properties and increasing solubility of poorly water-soluble drugs. The research presented in this paper concerns the preparation of binary combinations of chitosan (deacetylated chitin) with ...
Szymon Sip   +6 more
doaj   +1 more source

Home - About - Disclaimer - Privacy